Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients

Lancet

Volumn 350, Issue 9093, 1997, Pages 1729-1733

  Gane, Edward ^a,g   Saliba, Faouzi ^b   Valdecasas, Garcia J C ^c   O'Grady, John ^d   Pescovitz, Mark D ^e   Lyman, Susan ^f   Robinson, Charles A ^f  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HÔPITAL PAUL BROUSSE   (France)

^c HOSPITAL CLÍNIC   (Spain)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^f Roche Global Development   (United States)

^g AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; LYMPHOCYTE ANTIBODY;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOXICITY; FEMALE; GRAFT REJECTION; HERPES SIMPLEX; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; INCIDENCE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031581506     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)05535-9     Document Type: Article

References (31)

1. Patel R, Snydman DR, Rubin RH, Pescovitz M, Martin M, Paya CV. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996; 61: 1279-89.
2. Stratta RJ, Shaeffer MS, Markin RS, et al. Clinical patterns of cytomegalovirus disease after liver transplantation. Arch Surg 1989; 124: 1433-50.
3. Sutherland S, Bracken P, Wreghitt T, O'Grady J, Calne RY, Williams R. Donated organ as a source of cytomegalovirus in orthotopic liver transplantation. J Med Virol 1992; 37: 170-73.
4. Paya CV, Weisner RH, Hermans PE, et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. J Hepatol 1993; 18: 185-95.
5. Singh N, Dummer JS, Kusne S, et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 1988; 158: 124-31.
6. Portela D, Patel R, Larso-Keller JJ, et al. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis 1995; 171: 1014-18.
7. McCarthy JM, Karim MA, Keown PA. The cost impact of cytomegalovirus disease in renal transplant recipients. Transplantation 1993; 55: 1277-82.
8. O'Grady JG, Alexander GJ, Sutherland S, Williams R. CMV infection and donor/recipients HLA antigens: interdependent co-factors in the pathogenesiss of vanishing bile duct syndrome after liver transplantation. Lancet 1988; ii: 302-05.
9. Snydman DR, Werner BG, Dougherty NN, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomised, double-blind, placebo-controlled trial. The Boston Center for Liver Transplantation CMVIG Study Group. Ann Intern Med 1993; 119: 984-91.
10. Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. Ann Int Med 1994; 120: 375-81.
11. Martin M, Manez R, Linden P, et al. A prospective randomised trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994; 58: 779-85.
12. Stratta RJ, Shaefer MS, Cushing KA, et al. Successful prophylaxis of cytomegalovirus disease after primary CMV exposure in liver transplant recipients. Transplantation 1991; 5: 90-97.
13. Stratta RJ, Shaefer MS, Cushing KA, et al. A randomised prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch Surg 1992; 127: 55-64.
14. Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995; 346: 69-74.
15. Winston D, Imagawa D, Holt C, Kaldas F, Shaked A, Busuttil R. Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection. Transplantation 1995; 60: 1357-92.
16. Spector SA, Busch DF, Follansbee S, et al. Pharmacokinetic, safety and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. J Infect Dis 1995; 171: 1431-37.
17. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995; 333: 615-20.
18. The Oral Ganciclovir European and Australian Cooperative Study Group. Intravenous versus oral ganciclovir: European /Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. AIDS 1995; 9: 471-77.
19. Spector S, McKinley G, Lalezari J, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in patients with AIDS. N Engl J Med 1996; 334: 1491-97.
20. Gonwa T, Wicker K, Griffy KG, Jung D, Wong R. Pharmacokinetics and safety of oral ganciclovir in hepatic and renal transplant recipients [abstr]. In: Program and Abstracts of 14th Annual meeting of the American Society of Transplant Physicians. 1995: 184.
21. Merigan TC, Renlund DG, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992; 326: 1182-86.
22. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Int Med 1993; 118: 173-78.
23. Erice A, Chou S, Biron KK, Stanat SC, Balfour HH Jr, Jordan MC. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989; 320: 289-93.
24. van der Berg AP, van Son WJ, Haagsma EB, et al. Prediction of recurrent cytomegalovirus disease after treatment with ganciclovir in solid-organ transplant recipients. Transplantation 1993; 55: 847-51.
25. Drew WL, Milner RC, Busch DF. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991; 163: 716-19.
26. Boivin G, Erice A, Crane D, Dunn DL, Balfour HH Jr. Ganciclovir susceptibilities of cytomegalovirus isolates from solid organ transplant recipients with CMV viraemia after antiviral prophylaxis. J Infect Dis 1993; 168: 332-35.
27. Lurain NS, Ammons HC, Kapell KS, Yeldandi VV, Garrity ER, O'Keefe JP. Molecular analysis of human cytomegalovirus strains from two lung transplant recipients with the same donor. Transplantation 1996; 62: 497-502.
28. Rosen HR, Benner KG, Flora KD, et al. Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. Transplantation 1997; 63: 476-77.
29. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive gancilovir therapy to prevent cytomegalovirus disease in antibody-positive renal transplant recipients, Ann Int Med 1995; 123: 18-26
30. Balfour HH, Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320: 1381-87.
31. Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987; 317: 1049-54.